Global Somatostatin Analogs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 137207
  • calendar_today Published On: Jan, 2019
  • file_copy Pages: 111
  • list Pharmaceuticals and Healthcare

Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth.

Scope of the Report:

This report focuses on the Somatostatin Analogs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. Somatostatin can slow down hormone production, including many of the gut hormones, slows down the emptying of the stomach and bowel, controls the release of hormones made by the pancreas, including insulin and, slows down or stops the release of growth hormones. Rise in the research and development and launch of novel drug therapies are the factors driving the growth of somatostatin analogs over the forecast period.

The worldwide market for Somatostatin Analogs is expected to grow at a CAGR of roughly 4.9% over the next five years, will reach 3230 million US$ in 2023, from 2430 million US$ in 2017, according to a new study.

Market Segment by Manufacturers, this report covers

Novartis

Peptron

Chiasma

Ipsen Biopharmaceutical

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Octreotide

Lanreotide

Pasireotide

Market Segment by Applications, can be divided into

Acromegaly

Carcinoid Syndrome

Neuroendocrine Tumor

Cushing Syndrome

Others

There are 15 Chapters to deeply display the global Somatostatin Analogs market.

Chapter 1, to describe Somatostatin Analogs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Somatostatin Analogs, with sales, revenue, and price of Somatostatin Analogs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Somatostatin Analogs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Somatostatin Analogs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Somatostatin Analogs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Somatostatin Analogs Introduction

1.2 Market Analysis by Type

1.2.1 Octreotide

1.2.2 Lanreotide

1.2.3 Pasireotide

1.3 Market Analysis by Applications

1.3.1 Acromegaly

1.3.2 Carcinoid Syndrome

1.3.3 Neuroendocrine Tumor

1.3.4 Cushing Syndrome

1.3.5 Others

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Novartis

2.1.1 Business Overview

2.1.2 Somatostatin Analogs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Novartis Somatostatin Analogs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Peptron

2.2.1 Business Overview

2.2.2 Somatostatin Analogs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Peptron Somatostatin Analogs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Chiasma

2.3.1 Business Overview

2.3.2 Somatostatin Analogs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Chiasma Somatostatin Analogs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Ipsen Biopharmaceutical

2.4.1 Business Overview

2.4.2 Somatostatin Analogs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Ipsen Biopharmaceutical Somatostatin Analogs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Somatostatin Analogs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Somatostatin Analogs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Somatostatin Analogs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Somatostatin Analogs Manufacturer Market Share in 2017

3.3.2 Top 6 Somatostatin Analogs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Somatostatin Analogs Market Analysis by Regions

4.1 Global Somatostatin Analogs Sales, Revenue and Market Share by Regions

4.1.1 Global Somatostatin Analogs Sales and Market Share by Regions (2013-2018)

4.1.2 Global Somatostatin Analogs Revenue and Market Share by Regions (2013-2018)

4.2 North America Somatostatin Analogs Sales and Growth Rate (2013-2018)

4.3 Europe Somatostatin Analogs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Somatostatin Analogs Sales and Growth Rate (2013-2018)

4.5 South America Somatostatin Analogs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Somatostatin Analogs Sales and Growth Rate (2013-2018)

5 North America Somatostatin Analogs by Countries

5.1 North America Somatostatin Analogs Sales, Revenue and Market Share by Countries

5.1.1 North America Somatostatin Analogs Sales and Market Share by Countries (2013-2018)

5.1.2 North America Somatostatin Analogs Revenue and Market Share by Countries (2013-2018)

5.2 United States Somatostatin Analogs Sales and Growth Rate (2013-2018)

5.3 Canada Somatostatin Analogs Sales and Growth Rate (2013-2018)

5.4 Mexico Somatostatin Analogs Sales and Growth Rate (2013-2018)

6 Europe Somatostatin Analogs by Countries

6.1 Europe Somatostatin Analogs Sales, Revenue and Market Share by Countries

6.1.1 Europe Somatostatin Analogs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Somatostatin Analogs Revenue and Market Share by Countries (2013-2018)

6.2 Germany Somatostatin Analogs Sales and Growth Rate (2013-2018)

6.3 UK Somatostatin Analogs Sales and Growth Rate (2013-2018)

6.4 France Somatostatin Analogs Sales and Growth Rate (2013-2018)

6.5 Russia Somatostatin Analogs Sales and Growth Rate (2013-2018)

6.6 Italy Somatostatin Analogs Sales and Growth Rate (2013-2018)

7 Asia-Pacific Somatostatin Analogs by Countries

7.1 Asia-Pacific Somatostatin Analogs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Somatostatin Analogs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Somatostatin Analogs Revenue and Market Share by Countries (2013-2018)

7.2 China Somatostatin Analogs Sales and Growth Rate (2013-2018)

7.3 Japan Somatostatin Analogs Sales and Growth Rate (2013-2018)

7.4 Korea Somatostatin Analogs Sales and Growth Rate (2013-2018)

7.5 India Somatostatin Analogs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Somatostatin Analogs Sales and Growth Rate (2013-2018)

8 South America Somatostatin Analogs by Countries

8.1 South America Somatostatin Analogs Sales, Revenue and Market Share by Countries

8.1.1 South America Somatostatin Analogs Sales and Market Share by Countries (2013-2018)

8.1.2 South America Somatostatin Analogs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Somatostatin Analogs Sales and Growth Rate (2013-2018)

8.3 Argentina Somatostatin Analogs Sales and Growth Rate (2013-2018)

8.4 Colombia Somatostatin Analogs Sales and Growth Rate (2013-2018)

9 Middle East and Africa Somatostatin Analogs by Countries

9.1 Middle East and Africa Somatostatin Analogs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Somatostatin Analogs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Somatostatin Analogs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Somatostatin Analogs Sales and Growth Rate (2013-2018)

9.3 UAE Somatostatin Analogs Sales and Growth Rate (2013-2018)

9.4 Egypt Somatostatin Analogs Sales and Growth Rate (2013-2018)

9.5 Nigeria Somatostatin Analogs Sales and Growth Rate (2013-2018)

9.6 South Africa Somatostatin Analogs Sales and Growth Rate (2013-2018)

10 Global Somatostatin Analogs Market Segment by Type

10.1 Global Somatostatin Analogs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Somatostatin Analogs Sales and Market Share by Type (2013-2018)

10.1.2 Global Somatostatin Analogs Revenue and Market Share by Type (2013-2018)

10.2 Octreotide Sales Growth and Price

10.2.1 Global Octreotide Sales Growth (2013-2018)

10.2.2 Global Octreotide Price (2013-2018)

10.3 Lanreotide Sales Growth and Price

10.3.1 Global Lanreotide Sales Growth (2013-2018)

10.3.2 Global Lanreotide Price (2013-2018)

10.4 Pasireotide Sales Growth and Price

10.4.1 Global Pasireotide Sales Growth (2013-2018)

10.4.2 Global Pasireotide Price (2013-2018)

11 Global Somatostatin Analogs Market Segment by Application

11.1 Global Somatostatin Analogs Sales Market Share by Application (2013-2018)

11.2 Acromegaly Sales Growth (2013-2018)

11.3 Carcinoid Syndrome Sales Growth (2013-2018)

11.4 Neuroendocrine Tumor Sales Growth (2013-2018)

11.5 Cushing Syndrome Sales Growth (2013-2018)

11.6 Others Sales Growth (2013-2018)

12 Somatostatin Analogs Market Forecast (2018-2023)

12.1 Global Somatostatin Analogs Sales, Revenue and Growth Rate (2018-2023)

12.2 Somatostatin Analogs Market Forecast by Regions (2018-2023)

12.2.1 North America Somatostatin Analogs Market Forecast (2018-2023)

12.2.2 Europe Somatostatin Analogs Market Forecast (2018-2023)

12.2.3 Asia-Pacific Somatostatin Analogs Market Forecast (2018-2023)

12.2.4 South America Somatostatin Analogs Market Forecast (2018-2023)

12.2.5 Middle East and Africa Somatostatin Analogs Market Forecast (2018-2023)

12.3 Somatostatin Analogs Market Forecast by Type (2018-2023)

12.3.1 Global Somatostatin Analogs Sales Forecast by Type (2018-2023)

12.3.2 Global Somatostatin Analogs Market Share Forecast by Type (2018-2023)

12.4 Somatostatin Analogs Market Forecast by Application (2018-2023)

12.4.1 Global Somatostatin Analogs Sales Forecast by Application (2018-2023)

12.4.2 Global Somatostatin Analogs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Somatostatin Analogs Picture

Table Product Specifications of Somatostatin Analogs

Figure Global Sales Market Share of Somatostatin Analogs by Types in 2017

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery